ABSTRACT: Juvenile angiofibroma is an uncommon, benign, locally aggressive vascular tumor. It is found almost exclusively in young men. Common presenting symptoms include nasal obstruction and epistaxis. More advanced tumors may present with facial swelling and visual or neurological disturbances. The evaluation of patients with juvenile angiofibroma relies on diagnostic imaging. Preoperative biopsy is not recommended. The mainstay of treatment is resection combined with preoperative embolization. Endoscopic surgery is the approach of choice in early stages, whereas, in advanced stages, open or endoscopic approaches are feasible in expert hands. Postoperative radiotherapy (RT) or stereotactic radiosurgery seem valuable in long-term control of juvenile angiofibroma, particularly those that extend to anatomically critical areas unsuitable for complete resection. Chemotherapy and hormone therapy are ineffective. The purpose of the present review was to update current aspects of knowledge related to this rare and challenging disease.
INTRODUCTION
The cellular, vascular, and locally aggressive tumor that characteristically develops in the posterior nasal cavity of adolescent men 1 is generally referred to as juvenile nasopharyngeal angiofibroma. Because of previous uncertainty regarding the precise origin of the tumor, it has been described using various names in the literature. In 1847, Chelius 2 described this lesion as a "fibrous nasal polyp, which commonly occurs in persons around the time of puberty." It has also been known as juvenile nasopharyngeal angioma, 3 vascular fibroma, 4 juvenile nasopharyngeal hemangiofibroma, 5 juvenile fibroangioma, 6 and juvenile fibroma. 7 However, given the origin of the tumor from the pterygopalatine fossa close to the vidian canal, the term juvenile angiofibroma seems preferable and is used here.
Juvenile angiofibroma is regarded as a benign tumor. 1 Sarcomatous, malignant transformation is extremely rare and attributable to prior radiotherapy (RT). 8, 9 Transformation of a tumor in the absence of previous RT has been recently described. 9 Juvenile angiofibroma may be associated with significant morbidity because of the particular anatomic location and locally destructive growth pattern. Management may be complex because of the increased risk of severe hemorrhage. Therefore, the purpose of the present review was to explore the management of juvenile angiofibroma in the light of current knowledge and in conjunction with epidemiologic, pathobiologic, and diagnostic aspects.
Exceptional cases in women have also been described [13] [14] [15] [16] but should be subjected to rigorous pathologic and genetic review. The incidence seems higher in the Middle East and India than in Europe. 10, 11, 17 
Etiopathogenetic considerations
Hormonal and genetic factors have been considered to explain the almost exclusive occurrence of juvenile angiofibroma in young men. 18 Hormonal influences are controversial. On the one hand, juvenile angiofibroma expresses various levels of estrogen, progesterone, and androgen receptors 19 ; and an etiopathogenetic role for testosterone has been advocated. [20] [21] [22] Riggs and Orlandi 23 observed that exogenous testosterone can cause tumor growth at any time, even decades after treatment. On the other hand, correlations among proliferative index, hormonal receptors, age at diagnosis, and tumor stage or bleeding have not been established. 19, 24, 25 Thus, the significance of pubertyinduced testosterone levels in tumor development remains unclear.
Investigations of possible genetic events 18, 26 are usually based on small numbers of patients and clinical correlation is lacking. Chromosomal numeric gains and losses have been detected in both endothelial and stromal components of juvenile angiofibroma. 26 These include deletions in chromosome 17, which affect regions of the TP53 suppressor gene and human epidermal growth factor receptor 2 (HER-2)/NEU oncogene. 27 Wnt pathways may also be involved via somatic or germ-line mutations of CTNNB1 and APC, respectively. 28 Ponti et al 29 reported nuclear staining for b-catenin in juvenile angiofibromas, which is of interest because b-catenin is a coactivator of androgen receptors, whereas altered APC expression was only seen in juvenile angiofibromas associated with familial adenomatous polyposis (FAP). Except for the association with FAP, 18, 28, 30 juvenile angiofibroma may develop in patients with Gardner syndrome and chromosomal aberrations have been reported. 31 Juvenile angiofibroma overexpresses receptors for vascular endothelial growth factor (VEGFR-2), 29 which may explain the growth of the tumor vascular component. Immunoexpression of stromal tenascin-C (TNC) in tumor stroma correlates with vascular density and higher tumor stage and possibly influences angiogenesis. 32 Loss of syndecan-2 has also been reported, which could enhance the migration of tumor cells and account for difficulties in surgical control of tumor margins. 32 Other investigations drew attention to a correlation between overexpression of FGF18 and AURKB in stromal cells and downregulation of androgen receptors in endothelial cells. 26 A possible role for human herpes simplex virus-8 (HSV-8), Epstein-Barr virus (EBV), and human papillomavirus (HPV) has also been considered. 25 Although juvenile angiofibroma does not seem to be associated with HSV-8 or EBV, there is evidence of HPV infection at DNA and protein levels. 33 HPV is also likely to increase the cell proliferation rate in juvenile angiofibroma 33 and may be a possible etiologic or aggravating factor effecting early presentation/recurrent disease and accounting for variability in clinical behavior, respectively.
Except for sex and age preference, the characteristic location of juvenile angiofibroma is intriguing. This could be explained if the tumor is regarded as a vascular malformation related to incomplete regression of the first branchial arch artery. Remnants of the artery may be preserved at the area of the sphenopalatine foramen, the typical site of juvenile angiofibroma, and could be sensitive to growth stimulation around puberty resulting in juvenile angiofibroma. 34 The notion is further explored in "Pathology" below and can be reconciled with molecular events, although some authors consider it unlikely. 32 
Site of origin and progression routes
Juvenile angiofibroma usually originates in the posterior nasal cavity, near the basisphenoid and the superior margins of the sphenopalatine foramen. The tumor shows an expansive and destructive growth pattern and spreads to adjacent nasal cavity, nasopharynx, paranasal sinuses, orbit, and skull base through foramina and fissures. Normal tissues are displaced and affected by pressure rather than invasion. Dumbbell-shaped extension into the pterygopalatine space, masticator space, and infratemporal fossa often occurs. 35 Cavernous sinus or intracranial extension is noted in 10% to 20% of the cases. 36 Intradural involvement is exceptional.
Pathology
Grossly, juvenile angiofibromas appear as rounded or lobulated, reddish or red-purple masses, sessile or pedunculated. 37, 38 They are well circumscribed ( Figure 1A ), although nonencapsulated, and there may be areas of ulceration or purulent exudate on the surface. Depending on the degree of vascularity, the cut surface appears solid or spongy with smooth "cysts/openings" corresponding with distended vessels.
Histologically, juvenile angiofibroma shows vascular and stromal components ( Figure 1B) . 37, 39 The vessels range from narrow-caliber and slit-like to irregularly outlined ectatic channels in "stag horn" or "pericytomatous" arrangements ( Figure 1C ). They are lined by a single endothelial layer and variously surrounded by poorly developed "myoid" cells variably resembling smooth muscle fibers ( Figure 1D and 1E) . Elastic laminae or definite muscular coats are not seen, and a structural "leaky" appearance ( Figure 1F ) accounts for the finding of thrombi therein and clinical bleeding even after minor manipulation. The stroma is often moderately cellular and collagenous ( Figure  1G ). The cells are spindled, plump, stellate, or angular, often with dispersed chromatin and small nucleoli ( Figure  1H ), and varying in distribution between different tumors and areas of the same tumor. Multinuclear forms may be detected. The interstitial matrix ranges from fibrillary to hyalinized, and myxoid areas may be present ( Figure 1I ). Overall, cytology is bland, and significant atypia or mitotic activity is not seen ( Figure 1G ). Necrosis, if present, is attributable to preoperative embolization. Embolic material may be seen in vascular lumina ( Figure 1A ). Small nerves and seromucinous glands can be trapped within the growing tumor. The overlying epithelium is often respiratory epithelium, with areas of squamous metaplasia or ulceration. The latter results in reactive changes, like mixed inflammatory-cell infiltration and formation of vascular granulation tissue.
Electron microscopy shows a focal lack of pericytes, discontinuous basement membranes, and irregular muscular coat, which reinforces the notion of "leaky" vessels and suggests that juvenile angiofibroma is a vascular malformation rather than a neoplasm. 40 Stromal cells are often fibroblasts, although myofibroblasts are also present. The latter are demonstrable on immunohistochemistry for smooth muscle actin. 41, 42 The vascular endothelium expresses CD34, CD31, von Willebrand factor, and endoglin. 43, 44 The stromal cells do not stain for CD34. It has been suggested that microvessel density in juvenile angiofibroma assessed by means of immunohistochemistry for endoglin, correlates with recurrence. 44 Confirmation is desirable but clinical value, if any, remains to be seen. The expression of androgen receptors, VEGFR2 and tenascin in juvenile angiofibroma, has already been mentioned (see "Etiopathogenesis").
The histological diagnosis of juvenile angiofibroma does not usually pose a problem for the experienced head and neck pathologist, particularly when excised specimens are examined. Inflammatory sinonasal polyps, pyogenic granulomas, 45, 46 glomangiopericytomas, and solitary fibrous tumors should be considered in the differential diagnosis but, in our opinion, the diagnostic difficulties have been overemphasized, even in cases of hyalinized inflammatory sinonasal polyps. [47] [48] [49] [50] Distinction from the rare sinonasal vascular leiomyoma may be more challenging, although clinical setting, sex, age, and site should be of help. Diagnosis on superficial incisional biopsies may pose difficulties, particularly in the presence of superficial ulceration, but such biopsies must be avoided when juvenile angiofibroma is suspected (see "Clinical features and diagnosis" below).
Clinical features and diagnosis
Recurrent, unprovoked, painless, profuse, unilateral epistaxis (60%), and unilateral nasal obstruction (80%) with rhinorrhea is the usual clinical presentation. Nasal examination is recommended for every young man with these symptoms to exclude juvenile angiofibroma. Less common symptoms include headaches (25%) secondary to the obstruction of the paranasal sinuses, and conductive hearing loss secondary to serous otitis media from compression of the Eustachian tube. Progressive expansion leads to sinonasal symptoms and facial swelling (10% to 40%). 51 Visual and neurological deficits may appear when the orbit, skull base, or endocranium are affected. 52 Symptoms are generally present for 6 months to a year before diagnosis.
Modern imaging techniques enable earlier recognition, patients present at earlier stages, and compressive and neurological symptoms are less frequent. Still, up to 40% of cases are diagnosed at an advanced stage (see "Staging" below), with up to 17% showing intracranial extension. 53 Delay in presentation is attributable to the association of indolent symptoms of juvenile angiofibroma with more common diseases, such as rhinitis, sinusitis, and antrochoanal polyps. The average delay between symptom onset and surgery is around 12 to 14 months. 54 Preoperative diagnosis is based on clinical and imaging features; incisional biopsy may lead to massive bleeding and is not recommended. 55 Rhinoscopy usually reveals a reddish lobulated mass located at the back of the nasal cavity and the cavum, often lobulated and firm (see Figure 2).
Imaging
Routine preoperative imaging confirms the diagnosis, defines tumor extension and staging and assists in treatment planning. In addition, it is used postoperatively to assess tumor persistence or recurrence. 56 CT, MRI, and angiography assist in defining the location, the relationship to important neurovascular structures, and assessment of the blood supply to select the least traumatic approach for hemostatic control ( Figures 3  and 4 ). CT is superior in outlining bony landmarks and in demonstrating bone erosion and invasion of the sphenoid, a significant predictor of recurrence. CT is more accurate for intraoperative image-based navigation. It is useful to get a CT-angiogram for navigation because this will provide superior visualization of the internal carotid artery. An MRI is more useful for assessing soft tissues, invasion of bone marrow, and intracranial extension, it is also the preferred modality for follow-up because of the potential for differentiating postoperative reparative processes from recurrence.
CT often shows a soft tissue mass with bone remodeling or destruction, which originates near the sphenopalatine foramen and extends into adjacent nasopharynx and pterygopalatine fossa. The Holman-Miller sign, which is the forward bowing of the posterior wall of the maxilla, is found in 80% of juvenile angiofibromas but can also occur with other benign or malignant tumors. The pathognomonic sign of juvenile angiofibroma is erosion of the upper medial pterygoid plate, which is found in 98% of juvenile angiofibromas. 56 Contrast injection enables diffuse avid enhancement. On MRI, juvenile angiofibroma shows low and medium to high signal intensities on precontrast T1-weighted and T2-weighted sequences, respectively. Intralesional signal voids and intense enhancement after contrast injection reflect flow in enlarged vessels in keeping with a diagnosis of juvenile angiofibroma. Apparent diffusion coefficient (ADC) values are high and degenerative/cystic components may be seen. The use of MRI and fatsuppression sequences assist in detecting bone marrow edema, inversely related to surgical success. MRI is also useful in detecting intracranial, dural, and intracavernous extensions and shows the relations of the tumor to the internal carotid arteries and pituitary. Detection of dural involvement may be challenging, but should be suspected if enhancement is seen on postcontrast T1-weighted images. In addition, contrast-enhanced fluid-attenuated inversion recovery (FLAIR) sequences are reported to be sensitive in detecting leptomeningeal spread. 57 An MRI may finally assist in distinguishing fluid collections and inflammatory mucosal thickening of the paranasal sinuses from intrasinus tumor extension.
Kukwa et al 58 reported expression of somatostatin receptors (SSTRs) in juvenile angiofibroma and suggested that somatostatin (SST) analogues with an affinity for SSTR2 may be used in preoperative and postoperative assessment via 99m-technetium (99m-TC) octreotide scintigraphy. 
Angiography and embolization
Bilateral carotid angiography is required to assess the vascular supply of juvenile angiofibroma and allow embolization of feeding vessels before surgery. 59 Occlusion of feeders reduces intraoperative bleeding, a major cause of morbidity, and may shrink the tumor. This enables better visualization of the surgical field, particularly in an endoscopic setting, facilitates dissection, 60 and increases the chances of complete resection, a factor influencing recurrence. 61 Most authors endorse embolization, although a few question its value on the basis of possible distortion of tumor boundaries, leading to incomplete resection. 62, 63 Reservations apart, preoperative embolization is now regarded as an important component of management. It results in a 70% reduction of intraoperative blood loss, thus alleviating morbidity and the need for blood transfusions. 60, [64] [65] [66] Blood loss is significant with juvenile angiofibroma (mean, 1449 mL) and reinforces careful selection and preoperative workup of patients. 53 Wasl et al 67 reported that homologous blood transfusion can be avoided with preoperative cell saver and autologous blood banking. Others support the latter but caution against the former because of possible autoinoculation. 68 The vascular supply of juvenile angiofibroma largely derives from the external carotid artery and its internal maxillary and ascending pharyngeal branches. 69 Occasionally, juvenile angiofibroma is supplied by both external carotid arteries. 59, 70 Bilateral embolization of the internal maxillary arteries may be performed in such cases to prevent collateral blood supply. It is also noted that embolizing deep temporal branches of the external carotid artery that supply the temporalis muscle may compromise reconstruction. As tumors enlarge, additional blood supply is derived from branches of the internal carotid artery, predominantly the vidian artery. Although feeders from the internal carotid artery may be embolized, 51 the risk of serious complications, such as stroke, visual loss, facial paralysis, or carotid dissection is increased and is not routinely performed. The ophthalmic artery is not embolized because of the risk of visual loss.
Embolization should be performed 24 to 48 hours before surgery (see Figure 4) 71 and is usually effected via super-selective catheterization of supplying arterial branches. Embolic substances include polyvinyl alcohol (PVA), coils, microparticles, or liquid glue. The ethylenevinyl alcohol copolymer Onyx (ev3, Irvine, CA), shows technical advantages enabling deep penetration into the tumor, with more extensive tumor necrosis, embolization of large portions of the tumor via fewer catheterizations, and safe withdrawal of the catheter despite possible substantial reflux. 72 Successful arterial embolization with any of these embolic agents may be limited by vessel tortuosity, vasospasm, or prior loss of the internal maxillary artery or external carotid artery. If the tumor-feeding vessels are not accessible or cannot be safely embolized, direct intratumoral embolization under radiographic control may be undertaken. [73] [74] [75] Embolization is not without complications, the most serious being loss of vision secondary to occlusion of the central retinal artery. 76, 77 The majority of complications are transient and amenable to clinical management. 78 Transient hair loss in the occipital region from radiation exposure can be seen after embolization. 79 If preoperative tumor embolization cannot be performed, attempts should be made to reduce intraoperative bleeding via isolation and ligation of feeding vessels (mainly the internal maxillary artery) as part of the surgical approach before proper tumor dissection begins. Hypotensive general anesthesia, the use of radiofrequency coblation and other hemostatic devices, and meticulous dissection, as well as diathermy of the sphenopalatine artery would be helpful. [80] [81] [82] [83] Other surgical strategies for minimizing intraoperative blood loss include dividing the tumor into vascular segments, cauterization of the vidian artery contribution, and staging of surgery. 70 Advanced tumors with encasement of the internal carotid artery are at increased risk of vascular injury during surgery. Assessment of collateral blood flow and balloon occlusion testing of the artery can help identify patients who can tolerate loss of the artery if an injury occurs. Such information is helpful in determining the extent of surgery. In such cases, angiographic loss of the artery can be performed preemptively or only if an injury occurs. Most young patients will tolerate the loss of 1 carotid artery. Preoperative stenting of the vessel has also been used to decrease the risk of injury when there is tumor encasement by paragangliomas, and therefore, could be applied to juvenile angiofibroma. 84 
Staging systems
Various systems have been proposed; most are based on tumor expansion and intracranial extension.
11,85
Although none is universally endorsed, 86 that suggested by Radkowski et al 87 (modification of Sessions et al 88 ) enjoys popularity. Snyderman et al 89 introduced an interesting alternative that also emphasizes the significance of residual vascularity of the tumor after embolization (see Table 1 ).
35,87-91

Management
Surgical resection is regarded as the treatment of choice for all stages of uncomplicated primary and recurrent juvenile angiofibroma. 53 RT should be reserved for advanced tumors with a high risk of significant morbidity or residual/recurrent disease in neurocritical areas. 64 Hormone therapy and chemotherapy have been explored with little or no success. Spontaneous regression of untreated juvenile angiofibroma has been reported, [92] [93] [94] [95] [96] and observation of residual tumors that are difficult to resect is warranted until continued growth is confirmed. 97 
Surgery
Surgery aims to achieve tumor exposure and complete resection with the least possible morbidity. The extent of the initial resection influences recurrence rates. Multiple approaches based on tumor location and stage have been suggested. 98 All have advantages and limitations, and selection often depends on surgical skill and experience. It is likely that experienced surgeons would use conservative approaches for the resection of large juvenile angiofibromas. A detailed description of the different potential surgical approaches is beyond the scope of this review Conventional open surgery has a role in the management of juvenile angiofibromas with significant intracranial and infratemporal or temporal fossa extension, or encasement of the optic nerve or internal carotid artery entrapment. It is usually reserved for patients with Radkowski IIIB tumors. [99] [100] [101] [102] Anterior open approaches include transfacial and transpalatal approaches. External facial or palatal incisions can be avoided in most cases with the use of midfacial degloving approaches. Augmentation of the midfacial degloving approach with a craniofacial-subcranial approach or preauricular-subtemporal-infratemporal approach may be necessary for large tumors with extension to the anterior cranial fossa or middle cranial fossa, respectively. The facial translocation approach provides maximal access for midline tumors with lateral extension but has significant morbidity; equivalent results are obtained with a midfacial degloving approach combined with a lateral infratemporal approach. 103 A lateral transorbital approach with lateral orbitotomy is an alternative for limited lateral skull base involvement. The midfacial degloving approach provides simultaneous access through the nasal cavity and maxillary sinus on one or both sides. A disadvantage of this approach is the relatively poor access to the skull base behind the tumor. Although most intracranial lesions can be safely dissected from the dural surface, the complete extirpation of these tumors may be difficult if bleeding is severe. In these cases, the standard facial translocation approach is applicable. 104 Anterior and standard facial translocations, and the preauricular-subtemporalinfratemporal and craniofacial-subcranial approaches are further examined. The versatile facial translocation is the method of choice for large tumors extending to the infratemporal fossa or paranasal sinuses. It allows osteotomies that enable exposure of the sinonasal area and infratemporal fossa; and approaching the tumor from lateral and anteroposterior perspectives. 104 Poor access to the skull base behind the tumor is a disadvantage. Although most intracranial lesions can be safely removed because the pushing tumor border is easily dissected from the dura, complete extirpation may be difficult if bleeding is severe. In these cases, the standard facial translocation approach is applicable. 104 The preauricularsubtemporal-infratemporal approach provides lateral access for tumors that extend into the masticator space, infratemporal fossa, middle cranial fossa, parasellar region, or involve the greater wing of the sphenoid bone. 105 An orbitozygomatic osteotomy and elevation of the temporalis muscle provide exposure of the subtemporal skull base and lateral orbit (greater wing of sphenoid). After excision of the tumor, the temporalis muscle can be transposed to cover an exposed carotid artery or middle fossa dura. The craniofacialsubcranial approach is appropriate for intracranially extending juvenile angiofibromas affecting the floor of the anterior fossa, sellar region, or optic chiasm. 106 It is noted that the open procedures do not substantially affect the facial and cranial growth of the young patients. 107 Transnasal endoscopic approaches are now increasingly used, avoiding facial incisions and achieving low longterm morbidity and low recurrence rates. They are valuable in treating early and carefully selected advanced juvenile angiofibromas. 70, 108 When compared with open resection, they result in significantly less intraoperative blood loss. 109, 110 They do not preclude surgical cure 64, 65, [111] [112] [113] [114] and may allow access to deep structures not fully visualized during open surgery. 115, 116 En bloc resection is not necessary to achieve surgical cure and, by contrast, piecemeal resection can facilitate the approach to difficult anatomic areas. Initially, endoscopic approaches were used for the management of small (Radkowski stages I and II) tumors. [117] [118] [119] [120] [121] [122] The increase of endoscopic surgical skills together with advances in surgical instrumentation, imaging, and surgical navigation systems enabled, however, the indication of these approaches even for Radkowski stages IIIA and B or University of Pittsburgh Medical Center (UPMC) stages IV and V. 64, 65, 113, 114, 116, [123] [124] [125] [126] Despite endoscopic advances, challenges remain and there is no consensus on the management of advanced juvenile angiofibroma. Although craniofacial approaches have been the standard treatment, a recent review of surgical outcomes for juvenile angiofibroma with intracranial involvement indicated that endoscopic resection is feasible in expert hands. 53 Lateral extension of juvenile angiofibroma into the infratemporal fossa may be a relative contraindication for endoscopic surgery, 98 but the absence of adhesions to surrounding tissues may enable retraction of the tumor into the nasal cavity. 51, 64 Even limited intracranial penetration/dural invasion may be endoscopically approachable. 53 The debate continues and using endoscopy combined with transnasal, transfacial, and transcranial approaches may be a reasonable compromise. 127 Staging of surgery because of excessive intraoperative blood loss may be necessary for advanced tumors with significant blood supply from the internal carotid artery (UPMC stages IV and V), especially in young patients with a small blood volume. In such cases, it is preferable to excise the extracranial component of the tumor at the first stage and address the intracranial component or internal carotid artery involvement in subsequent stages.
Fortunately, surgical complications are usually rare. Complications such as hypoesthesia V2/V3, VI nerve palsy, lacrimal duct dysfunction, trismus, sinusitis, nasal crusty, septal perforation, or the need of blood transfusions are not directly linked to the endoscopic procedure, but to the extent of surgery. 70, 126 Complications of the endoscopic approach are similar to those reported after total sphenoethmoidectomy. 11 Specifically, a loss of tearing causing a dry eye has been specifically related to endonasal removal of juvenile angiofibroma, probably because of damage to branches of the sphenopalatine ganglion or the ganglion itself. 128, 129 Regarding open approaches, a review of these open procedures reported no evidence of arrest in facial and cranial growth in young patients. 107 
Radiotherapy
In general, surgical excision is the preferred treatment for all juvenile angiofibroma, regardless of stage, and RT should be avoided because of the unknown long-term effects in a young patient population. RT may be considered for advanced, incompletely resectable juvenile angiofibroma and cases with a high morbidity of resection. Examples include tumors with significant intracranial extension and encasement of the internal carotid artery. The dose fractionation schedule is approximately 36 Gy at 1.8 Gy per once-daily fraction. Lower doses correlate with higher recurrence rates. 131 Intensity-modulated RT (IMRT) may be used to create a conformal dose distribution to minimize the dose to adjacent tissues. Alternatively, proton RT may be used to create an even tighter dose distribution to further reduce the risk of late effects in these young patients. Local control rates after definitive RT range from 85% to 91% with a low risk of severe late complications. 83, [131] [132] [133] Stereotactic radiosurgery is not appropriate as a sole modality to treat juvenile angiofibromas because treating a large incompletely resected mass with a single high dose of irradiation would likely result in a higher risk of late complications. [132] [133] [134] However, it could be considered for minimal, well-defined residual tumors after incomplete resection. The disadvantages of stereotactic radiosurgery is a risk of marginal miss because of the necessarily tight dose distribution and a higher risk of late complications compared with conventionally fractionated RT. Stereotactic hypofractionated RT using 5 or fewer fractions has the same disadvantages compared to stereotactic radiosurgery.
In patients with advanced-stage juvenile angiofibromas that are considered unresectable because of involvement of critical structures, an alternative to primary RT is excision of the extracranial portion of the tumor, leaving a small residuum in critical areas. This may minimize the radiation field and potential morbidity of RT. A potential disadvantage of primary RT for large "inoperable" tumors is the difficulty of subsequent surgery if there is progressive tumor growth. However, the likelihood of progression after RT is low and the risk of increased complications after 36 Gy at 2 Gy per fraction is probably modest. 125 After unanticipated incomplete resection or recurrent juvenile angiofibroma after prior surgery, RT is a reasonable option. 129, [135] [136] [137] As is the case with other benign tumors, such as paragangliomas and meningiomas, the tumor either slowly regresses incompletely or remains stable after successful RT. The main risk after RT is a radiation-induced malignancy, such as a sarcoma. The risk is probably about 1 in 500 with a latency period of 7 to 10 years or longer. 8, 131, 134, 138 Other potential complications of RT include growth retardation, panhypopituitarism, temporal lobe necrosis, cataracts, and radiation keratopathy. 133 However, the risk of late complications is very low with the dose-fractionation schedules used. In contrast, if a patient is at high risk for severe complication associated with surgery, it occurs immediately during the procedure or perioperatively. 133 
Chemotherapy and hormonal therapy
Chemotherapy or hormone therapy is not routinely recommended. 139 Chemotherapy has been suggested for recurrences and selected cases with aggressive growth. 140, 141 Hormonal therapy holds attraction because of the possible involvement of androgen receptors in the etiopathogenesis of juvenile angiofibroma (see above). In post-pubertal patients, flutamide, an androgen receptor antagonist, has been used preoperatively to achieve partial regression of the tumor from adjacent vital structures and allow a more conservative surgical approach. 142 However, others failed to confirm these results. 143 Expression of SSTRs in juvenile angiofibroma suggests that their subtyping may allow the use of specific SST analogues to treat residual, recurrent, and inoperable tumors. 58 Expression of other receptors 55, 144 indicates similarly variable potential. Tamoxifen, an estrogen receptor antagonist, inhibits proliferation of cultured juvenile angiofibroma stromal cells 141 ; however, the side effects of tamoxifen preclude its clinical application in juvenile angiofibroma. Bevacizumab, a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), may also be of value, but clinical data are lacking. 145 An untested but intriguing option would be glucocorticoids as they seem able to downregulate VEGF and reduce microvascular density and tumor volume; and their receptors are upregulated in juvenile angiofibroma. 146 
Results and follow-up
Most, if not all, recurrences are due to incomplete resection of the primary tumor. 147 The rate of residual disease varies from 13% to 50%. 64 Although it may be difficult to distinguish between residual tumor and new tumor growth, 146 the likelihood of a second primary juvenile angiofibroma is remote. Residual disease may not grow or even undergo involution. 60, 148 On postoperative CT and/or MRI scan, residual/recurrent disease appears as areas of contrast enhancement, but healing processes may show similar appearances and distinction is a major radiological challenge. 11, 126, 149 Chagnaud et al 149 formulated guidelines for follow-up. If the patient is asymptomatic, rhinoscopy is negative and imaging shows no residual mass 3 to 4 months after surgery, clinical review alone is recommended. If the clinical signs/symptoms suggest recurrent/residual tumor, a mass is visualized on rhinoscopy, and CT or MRI confirm tumor and indicate its extent, a second operation is performed. Finally, if the patient is asymptomatic, rhinoscopy is negative and enhancement outside the nasopharyngeal cavity is seen on the first radiological examination 3 or 4 months postoperatively, further imaging is undertaken 3 to 6 months later. Then, if the enhancement has decreased in size and/or intensity, a third imaging study follows after 6 months; in case of resolution clinical review is adequate; if the enhancement remains stable, periodical imaging twice a year is recommended; if the enhancement has increased in size, second surgery or RT are indicated. Langdon et al 126 do not support further surgery for intracranial remnants unless there is a measurable tumor growth or new symptoms.
Recurrence is usually observed within 6 to 36 months after primary therapy, 53, 110, 126, 150 which supports a minimum follow-up of 3 years. 11 Most investigators use a combination of rhinoscopy and MRI for at least 5 years postoperatively, but periods of follow-up vary between institutions. 64, 151 Nevertheless, early detection relates to better outcomes, and some authors advocate imaging within the first month postoperatively (even immediately after packing is removed) to detect residual disease. 152 This may improve its distinction from later healing processes. 111 Early detected residual disease usually requires minimally invasive surgery and the need for repeating embolization or RT can be avoided.
Recurrences are observed in approximately 18% to 45% of the patients and depending on size, extent of tumor, and surgical approach. Most patients (86%) would be expected to be free of disease during long-term follow-up. 10, 17, 53, 118 The likelihood of recurrence is particularly high in patients with intracranial extension. 147 Endoscopic recurrence rates seem lower than those of open surgery, although this may reflect the bias of earlystage tumors being more likely to be treated endoscopically. However, there is no difference in recurrence rate when controlling for tumor extent. 109, 114 Recurrence rates for patients with stages I and II lesions are between 0 and 7%, according to the majority of publications. 62, 65, 113, 114, 124 Encouraged by these results, technological progress, and increasing endoscopic skills, some authors approached advanced juvenile angiofibroma endoscopically with similar outcomes. 64, 126 Recurrence rates seem related to involvement of specific sites. The more sites involved, the higher the probability of tumor persistence. 126 Involvement of the skull base, extension into the pterygoid fossa and basisphenoid, erosion of the clivus, intracranial extension medial to the cavernous sinus, invasion of the sphenoid diploe through a widened pterygoid canal, feeders from the internal carotid artery, young age, and incomplete surgery are factors associated with increased risk of recurrence. 40, 108, 110, 150, 153 Howard et al 154 emphasized the significance of residual tumor in the basisphenoid and base of pterygoids and that meticulous removal led to cure in the majority of cases. Lloyd et al 56 reported that 60% of juvenile angiofibroma expand posteriorly along the pterygoid canal with invasion of the cancellous bone of the sphenoid and noted that 93% of recurrences occurred in patients with invasion of sphenoid diploe. Meticulous subperiosteal dissection and drilling of these areas assist in complete removal and avoiding recurrences. 64, 111, 150, 151 Thakar et al 155 reported that involvement of the vidian canal is almost universal in juvenile angiofibroma and may not be detected on CT; this site may still harbor microscopic residual tumor after an apparently complete resection and should receive particular surgical attention to reduce the chances of recurrence.
Second surgery, whether open or endoscopic, seems the best option if chances for extirpating residual/recurrence tumor are reasonably high. 60 Attempts at removing remnants from critical areas (cavernous sinus, internal carotid artery) do not seem justified because of significant morbidity. 65, 150, 153 Although residual or recurrent tumor may also be treated with RT or stereotactic radiosurgery with acceptable morbidity, a "wait and see" policy may be adopted. 53, 64 Prospective investigations are needed to determine the optimal strategy.
CONCLUSION
Juvenile angiofibroma is a rare and complex disease that may cause significant morbidity in young patients. Improved surgical and RT techniques and advances in imaging and preoperative embolization have influenced management. Treatment planning depends on patient age, low likelihood of spontaneous involution, expected surgical morbidity, RT side effects, and risk of recurrence.
The benign yet aggressive nature of the tumor poses a dilemma, as the price of a cure must not be worse than the disease itself. Surgery is the main therapeutic option. To provide the best possible care, patients with juvenile angiofibroma should be treated in clinical referral centers specialized in skull-base surgery to achieve best results in regard to complete resection and low morbidity; such centers should include a multidisciplinary team consisting of ear, nose, and throat surgeons, neurosurgeons, radiotherapists, medical oncologists, neuroradiologists, and pathologists. Endoscopic excision is preferable for early-stage tumors because of decreased morbidity. The selection of open or endoscopic approaches for more advanced tumors is very dependent on the experience of the surgical team. In these cases, the best results may be achieved with a combination of open and endoscopic approaches. RT or stereotactic radiosurgery after incomplete resection is valuable for long-term control of extensive juvenile angiofibroma involving vital structures. Although definitive RT is a treatment option for extensive, incompletely resected juvenile angiofibroma, resectability is subjective based on the abilities of the surgical team. Hormone therapy and chemotherapy have been nearly abandoned because of ineffectiveness and significant toxicity.
Although, in the hands of experienced teams, the management of most of these tumors by endoscopic technique can achieve complete resection with minimal blood loss, low rates of recurrence, and morbidity, some advanced juvenile angiofibromas are challenging. The development of new hemostatic materials and the increase of the safety and efficacy of the preoperative embolization techniques will address advanced juvenile angiofibroma more safely. Moreover, genetic analyses comprising at least of a panel of druggable gene products, if not genomewide, would be a promising addition to open up possibilities for targeted therapy. On the basis of these advances, combined with the development of novel targeted therapies, personalized therapeutic opportunities will become available to treat residual or recurrent juvenile angiofibroma or when juvenile angiofibroma involves vital structures with high surgical morbidity.
